Cell Biotech Co. Ltd (049960) — Cash Flow-to-Debt Ratio
Cell Biotech Co. Ltd (049960) has a Cash Flow-to-Debt Ratio of 0.56x as of September 2025, meaning its operating cash flow of ₩4.15 Billion could theoretically repay 1% of its total liabilities (₩7.46 Billion) in one year. See free cash flow generation of Cell Biotech Co. Ltd to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cell Biotech Co. Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Cell Biotech Co. Ltd across 14 annual periods. Also explore Cell Biotech Co. Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Cell Biotech Co. Ltd (2011–2024)
Year-by-year debt coverage analysis for Cell Biotech Co. Ltd. For market capitalisation and broader financial context, see Cell Biotech Co. Ltd stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 3.09x | ₩19.27 Billion | ₩6.23 Billion | ▲ +127.8% |
| 2023 | 1.36x | ₩7.82 Billion | ₩5.76 Billion | ▼ -17.9% |
| 2022 | 1.65x | ₩12.81 Billion | ₩7.75 Billion | ▼ -31.3% |
| 2021 | 2.41x | ₩14.89 Billion | ₩6.19 Billion | ▲ +33.8% |
| 2020 | 1.80x | ₩9.56 Billion | ₩5.32 Billion | ▼ -17.3% |
| 2019 | 2.18x | ₩10.23 Billion | ₩4.70 Billion | ▲ +0.0% |
| 2018 | 2.18x | ₩13.98 Billion | ₩6.42 Billion | ▼ -39.3% |
| 2017 | 3.59x | ₩22.53 Billion | ₩6.28 Billion | ▲ +27.1% |
| 2016 | 2.82x | ₩17.99 Billion | ₩6.38 Billion | ▼ -3.9% |
| 2015 | 2.94x | ₩18.24 Billion | ₩6.21 Billion | ▲ +55.4% |
| 2014 | 1.89x | ₩9.91 Billion | ₩5.24 Billion | ▼ -23.3% |
| 2013 | 2.46x | ₩8.99 Billion | ₩3.65 Billion | ▲ +55.1% |
| 2012 | 1.59x | ₩6.17 Billion | ₩3.88 Billion | ▲ +45.1% |
| 2011 | 1.10x | ₩5.45 Billion | ₩4.98 Billion | — |